Patents by Inventor Martin Purpura

Martin Purpura has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12161654
    Abstract: The present invention provides a composition comprising an acidic formulation containing ?-hydroxy-?-methylbutyrate (HMB), preferably in the free acid form, Vitamin D and a stabilizing excipient, wherein the Vitamin D is stabilized against degradation.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: December 10, 2024
    Assignee: Metabolic Technologies, LLC
    Inventors: John Rathmacher, Martin Purpura
  • Patent number: 12133920
    Abstract: The disclosed are shelf-stable beta-hydroxyisovaleric acid containing soft gel compositions and methods for making such compositions. In certain aspects, disclosed compositions comprise a plant-based capsule shell and a liquid formulation comprising beta-hydroxyisovaleric acid and at least one excipient, wherein the soft gel capsule is shelf-stable. In certain aspects, the excipient is selected from selected from choline salt, betaine, phosphatidylcholine, alpha-glycerophosphocholine, carnitine, adenosine 5?-triphosphate, or a combination thereof.
    Type: Grant
    Filed: March 30, 2021
    Date of Patent: November 5, 2024
    Assignee: TSI Group Co. Ltd.
    Inventors: Martin Purpura, Ralf Jäger, Jie Gu, Xiong Zheng, Lingwei Dai, Yaohua Zhang
  • Publication number: 20240299484
    Abstract: Disclosed herein are compositions and methods for promoting weight loss and/or preventing or obesity; improving athletic performance/endurance; improving muscle function; improving cognitive function; promoting weight management; improving cardiovascular health; improving blood flow; reducing inflammation; and/or immune modulation. In certain aspects, the disclosed method comprises administering a composition to a subject comprising combinations of dileucine and paraxanthine and/or dileucine and L-arginine and/or dileucine and leucine.
    Type: Application
    Filed: March 11, 2024
    Publication date: September 12, 2024
    Inventors: Ralf Jäger, Martin Purpura, Shawn D. Wells, Kylin Liao
  • Publication number: 20240216381
    Abstract: The disclosed compositions, systems and methods relate to compositions for human consumption and comprise a combination of paraxanthine and/or 1-methylxanthine and chlorogenic acid and optionally other compounds that modulate the effects of a combination of paraxanthine and/1-methylxanthine and chlorogenic acid. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of cognitive performance, mood, and/or sleep.
    Type: Application
    Filed: December 21, 2023
    Publication date: July 4, 2024
    Inventors: Ralf Jäger, Martin Purpura, Shawn D. Wells, Kylin Liao
  • Publication number: 20240033269
    Abstract: The disclosed technology relates generally to compositions, methods, and system for utilizing paraxanthine alone and in combination for use in enhancing immune function and/or inhibiting inflammation through administration of a paraxanthine-containing composition to a subject. More particularly, the disclosure relates to paraxanthine and other compounds, whether produced synthetically or derived from natural sources, and use of these compounds to provide physiological benefits, which may vary according to paraxanthine concentration and the presence of synergists and antagonists.
    Type: Application
    Filed: July 28, 2023
    Publication date: February 1, 2024
    Inventors: Ralf Jäger, Kylin Liao, Shawn D. Wells, Martin Purpura
  • Publication number: 20230165868
    Abstract: Paraxanthine-based compositions for muscle enhancement. Paraxanthine-based compositions for enhancing nitrogen signaling. Paraxanthine-based compositions for enhancing muscle glycogen.
    Type: Application
    Filed: November 28, 2022
    Publication date: June 1, 2023
    Inventors: Ralf Jäger, Martin Purpura, Shawn D. Wells, Kylin Liao
  • Publication number: 20230113817
    Abstract: Described herein are compositions for reducing body weight, reducing body fat, improving body composition and/or preventing obesity and related conditions. In certain aspects, the compositions comprise dileucine, and a pharmaceutically acceptable carrier thereof. In certain embodiments, the composition comprises dileucine and leucine. In further aspects, the dileucine is present from about 10% to 90% (w/w). In further aspects, the dileucine is present from about 20% to 80% (w/w). In further aspects, wherein the dileucine is present from about 30% to 70% (w/w). In further aspects, the dileucine is present from about 40% to 60% (w/w).
    Type: Application
    Filed: October 12, 2022
    Publication date: April 13, 2023
    Inventors: Ralf Jäger, Shawn D. Wells, Kylin Liao, Martin Purpura
  • Publication number: 20230115966
    Abstract: The disclosed compositions, and methods relate to compositions for human consumption and comprising paraxanthine and a cholinergic agent and/or theanine. The disclosed compositions are useful promoting cognitive function, energy, athletic performance and providing neuroprotective anti-oxidative effects.
    Type: Application
    Filed: October 13, 2022
    Publication date: April 13, 2023
    Inventors: Shawn Wells, Ralf Jager, Kylin Liao, Martin Purpura
  • Publication number: 20230072854
    Abstract: The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises paraxanthine and optionally other compounds that modulate the effects of paraxanthine. Uses for the paraxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
    Type: Application
    Filed: January 25, 2021
    Publication date: March 9, 2023
    Inventors: Martin Purpura, Shawn D. Wells, Ralf Jäger, Kylin Liao
  • Publication number: 20230053297
    Abstract: Disclosed herein in is a method of increasing plasma dileucine levels in a subject comprising administering to the subject an effective amount of a composition comprising leucine. In certain embodiments, the composition does not comprise dileucine. In certain embodiments, the amount of increase in plasma dileucine is greater than that resulting from administering a protein supplement comprising a comparable amount of leucine. In certain implementations, administration of the composition results in an increase in plasma dileucine that is from about 10% to about 50% greater than from administering a protein supplement comprising a comparable amount of leucine.
    Type: Application
    Filed: July 29, 2022
    Publication date: February 16, 2023
    Inventors: Ralf Jager, Martin Purpura, Shawn D. Wells, Kylin Liao
  • Publication number: 20230033911
    Abstract: The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises a combination of paraxanthine and tyrosine and/or taurine and optionally other compounds that modulate the effects of a combination of paraxanthine and tyrosine and/taurine. Further disclosed are methods of use of the foregoing compositions for improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
    Type: Application
    Filed: July 27, 2022
    Publication date: February 2, 2023
    Inventors: Ralf Jäger, Martin Purpura, Shawn D. Wells, Kylin Liao
  • Publication number: 20230037138
    Abstract: The disclosed compositions methods relate to a dietary supplement for subjects with slow caffeine metabolism and comprises paraxanthine and optionally other compounds that modulate the effects of paraxanthine. Uses for the paraxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite in a slow caffeine metabolizer subject.
    Type: Application
    Filed: July 27, 2022
    Publication date: February 2, 2023
    Inventors: Ralf Jäger, Martin Purpura, Shawn D. Wells, Kylin Liao
  • Publication number: 20220395522
    Abstract: Methods of use and compositions comprising a source of glucosamine are disclosed. The administration of the compositions provides for favorable trends towards improvements in gastrointestinal functional outcomes. The use of the glucosamine compositions increases nitrogen retention, as well as prevent, eliminate, and/or reduce bacterial diversity within the gastrointestinal microbiome. The source of glucosamine may be non-shellfish derived, and provide significant improvements in gastrointestinal symptoms such as, stomach bloating, constipation, and hard stools.
    Type: Application
    Filed: June 3, 2022
    Publication date: December 15, 2022
    Inventors: Ralf Jäger, Martin Purpura, Jingshi Zhou, Shixiong Ji, Larry Kolb
  • Publication number: 20220339213
    Abstract: Disclosed herein is method for increasing vitamin B12 levels in a subject comprising administering to the subject a composition comprising: at least one strain of bacteria wherein the at least one strain of bacteria comprises Propionibacterium freudenreichii UF (UF1). In certain embodiments, the UF1 is probiotic. In certain implementations, the administration of the composition increases the subject's serum B12 levels by at least about 10% relative to the subject's serum B12 level prior to administration of the composition. In further embodiments, the administration of the composition confers at least on benefit on the subject selected from; an increase in serum levels of at least one of vitamin B2, B5, B6, B9, and/or B12; an increase in at least one of tryptophan, tyrosine, phenylalanine; increased propionic acid, immune system modulation and/or augmentation, regulation of TH17 cells; and/or reduction in pro-inflammatory metabolites.
    Type: Application
    Filed: April 27, 2022
    Publication date: October 27, 2022
    Inventors: Sebastian Balcombe, Ralf Jäger, Martin Purpura
  • Publication number: 20220331327
    Abstract: Disclosed herein is a method for increasing video game performance in a subject by administering to the subject with a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. Further disclosed herein is a method for enhancing mood of a subject during electronic gameplay or preventing decrease in mood of a subject during electronic game play comprising administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, administration of the composition to the subject decreases, or prevents the increase of, one or more of tension, depression, anger, fatigue and/or confusion in the subject during electronic game play relative to a subject who has not been administered the composition.
    Type: Application
    Filed: March 31, 2022
    Publication date: October 20, 2022
    Inventors: Ralf Jäger, Martin Purpura, Shawn D. Wells, Kylin Liao
  • Publication number: 20220331328
    Abstract: The disclosed compositions, systems and methods relate to a dietary supplement for human consumption and comprises 1-methylxanthine and optionally other compounds that modulate the effects of 1-methylxanthine. Uses for the 1-methylxanthine-containing supplements contain improvement of at least one of endurance performance, mood, vigor, lipolysis, energy expenditure, exercise performance, and/or decreased appetite.
    Type: Application
    Filed: April 7, 2022
    Publication date: October 20, 2022
    Inventors: Ralf Jäger, Martin Purpura, Shawn Wells, Kylin Liao
  • Publication number: 20220305019
    Abstract: Disclosed herein are methods for promoting weight loss in a subject by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain aspects, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further aspects, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, weight loss is promoted through inducing thermogenesis in the subject. In further embodiments, weight loss is promoted through enhancing lipolysis in the subject. According to certain implementations, administration of the composition to the subject decreases the respiratory quotient in the subject by at least about 10%.
    Type: Application
    Filed: March 22, 2022
    Publication date: September 29, 2022
    Inventors: Martin Purpura, Ralf Jäger, Shawn Wells, Kylin Liao
  • Publication number: 20220305020
    Abstract: Disclosed herein are compositions and methods for attenuating stress-induced mental fatigue in subject in need thereof by administering to the subject a composition comprising from about 2 mg to about 800 mg of paraxanthine. In certain embodiments, paraxanthine is present in the composition in amount from about 20 mg to about 600 mg. In further embodiments, paraxanthine is present in the composition in amount from about 50 mg to about 400 mg. According to certain embodiments, fatigue attenuated by the instantly disclosed method is a result of physical stress on the subject. Physical stresses that may result in mental fatigue include, but are not limited to, periods of intense exercise.
    Type: Application
    Filed: March 28, 2022
    Publication date: September 29, 2022
    Inventors: Ralf Jäger, Martin Purpura, Shawn Wells, Kylin Liao
  • Publication number: 20220110903
    Abstract: Compositions and methods of treatment and prevention for trauma-related brain injury are disclosed herein. In certain aspects, disclosed is a method for preventing, alleviating or treating trauma-related brain injury in a subject in need thereof comprising administering to the subject a composition comprising docosahexaenoic acid and eicosapentaenoic acid.
    Type: Application
    Filed: September 20, 2021
    Publication date: April 14, 2022
    Inventors: Martin Purpura, Ralf Jäger, Mark Olson
  • Publication number: 20220040205
    Abstract: The present invention provides a composition comprising an acidic formulation containing ?-hydroxy-?-methylbutyrate (HMB), preferably in the free acid form, Vitamin D and a stabilizing excipient, wherein the Vitamin D is stabilized against degradation.
    Type: Application
    Filed: February 23, 2021
    Publication date: February 10, 2022
    Inventors: John Rathmacher, Martin Purpura